The United Kingdom and the United States have established a key trade agreement that will ensure zero tariffs on UK medicine products going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the NHS. This move secures that tariffs on these key goods will remain at zero for a period of three years.
This development is in response to previous statements to dramatically increase tariffs on patented drug products, with figures mentioned as high as double the cost.
"This arrangement between the Britain strengthens the global environment for innovative medicines and brings much-needed fairness to transatlantic medicine commerce," a statement noted.
Commercial Impact
Drugs are one of the Britain's biggest goods shipped to the America, which is by far the biggest buyer for large UK drugmakers.
Export figures indicate that in the year prior to last September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that span.
"This agreement protects work, boosts capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The deal involves several key pledges from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments were more than twenty percent.
Industry Background
The pact comes amid a ongoing tension between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were exacerbated by assertions that American patients were charged significantly more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a proportion of its resources over the previous ten-year period.
